SOPHIRIS BIO INC. | 2013 | FY | 3


The following table breaks down the remaining unpaid milestone payments by indication or, in the case of milestones not associated with a specific indication, by triggering events and by involvement of the Company:

 

     Milestone Payments
Involving Performance
of Company
Obligations
     Milestone Payments Not
Involving Performance
of Company
Obligations
 

Milestones by Indication

     

BPH

     —         $ 12 million   

Prostate cancer

     —         $ 21 million   

Prostatitis and other diseases of the prostate

     —         $ 21 million   

Milestones Not Associated with an Indication

     

Gross sale targets

     —         $ 8 million   

Regulatory approvals

   $ 5 million        —     

us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock